NEW YORK (GenomeWeb) – DiagnoCure today announced an asset purchase agreement in which it will sell its PCA3 prostate cancer biomarker to Hologic's wholly-owned subsidiary Gen-Probe.

Gen-Probe will acquire all assets related to the biomarker as well as right of first refusal to license DiagnoCure's high-volume multi-marker prostate cancer test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.